Editor Note: For more information about this release, please scroll to bottom.
NEW YORK, September 2, 2014 /PRNewswire/ --
Today, Analysts Review released its research reports regarding WellPoint Inc. (NYSE: WLP), Tekmira Pharmaceuticals Corporation (NASDAQ: TKMR), Zoetis Inc. (NYSE: ZTS), Sanofi SA (NYSE: SNY) and GlaxoSmithKline plc (NYSE: GSK). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6142-100free.
--
WellPoint Inc. Research Reports
WellPoint Inc. (WellPoint) posted on the Events and Webcasts section of its official website that it will participate in the upcoming FBR Inaugural Healthcare Conference on September 3, 2014. The full research reports on WellPoint are available to download free of charge at:
http://www.analystsreview.com/Sep-02-2014/WLP/report.pdf
--
Tekmira Pharmaceuticals Corporation Research Reports
On August 20, 2014, Tekmira Pharmaceuticals Corporation (Tekmira) announced the publication of data in a peer-reviewed scientific journal, highlighting positive results in an animal model of Marburg virus infection enabled by Tekmira's lipid nanoparticle (LNP) technology. According to the Company, Tekmira, along with its collaborators at the University of Texas Medical Branch at Galveston, U.S.A, published data demonstrating complete protection of nonhuman primates against lethal Marburg virus-Angola hemorrhagic fever (MARV-Angola) when treatment began even up to three days following infection. Dr. Mark Murray, Tekmira's President and CEO, said, "These positive findings build upon our extensive work in anti-viral RNAi therapeutics and provide further validation of our strong LNP product platform, which includes RNAi therapeutics addressing chronic Hepatitis B infection and lethal hemorrhagic fever viruses." The full research reports on Tekmira are available to download free of charge at:
http://www.analystsreview.com/Sep-02-2014/TKMR/report.pdf
--
Zoetis Inc. Research Reports
On August 27, 2014, Zoetis Inc. (Zoetis) announced that it has received a full license from the U.S. Department of Agriculture (USDA) to sell Poulvac® Bron GA 08, the first commercially available vaccine to reduce disease caused by Georgia 2008 (GA 08) Type infectious bronchitis virus (IBV) in poultry. Zoetis informed that the receipt of license was based on clinical data showing that the vaccine meets USDA's standards for safety, efficacy, purity and potency. According to the Company, the full license follows USDA's provision of a conditional license in fall of 2013, which authorized the vaccine's sale in states affected by GA 08. Kalen Cookson, DVM, MAM, a technical services veterinarian working for Zoetis, said, "Thanks to the continued support of industry, the USDA and the university, which provided the viral isolates on which the vaccine is based, we are pleased to offer our customers a fully licensed vaccine for GA 08 before winter, when disease challenge is highest." The full research reports on Zoetis are available to download free of charge at:
http://www.analystsreview.com/Sep-02-2014/ZTS/report.pdf
--
Sanofi SA Research Reports
On August 19, 2014, Sanofi SA (Sanofi) reported that its subsidiary Genzyme has received the U.S. Food and Drug Administration (FDA) approval for Cerdelga™ (eliglustat) capsules, the only first-line oral therapy for certain adult Gaucher disease type 1 patients. The Company informed that FDA's approval is based on efficacy data from two positive Phase 3 studies for Cerdelga: one in patients new to therapy, and the other in patients switching from approved enzyme replacement therapies. Further, the Cerdelga clinical development program is the largest ever conducted in Gaucher disease, with approximately 400 patients treated in 29 countries. David Meeker, M.D., President and CEO, Genzyme, said, "More than twenty years ago, Genzyme introduced the world's first treatment for Gaucher disease. We are proud to build on this legacy and continue to improve Gaucher patients' lives through ongoing research and new therapies. The approval of Cerdelga represents our unwavering commitment to the Gaucher patient community." The full research reports on Sanofi are available to download free of charge at:
http://www.analystsreview.com/Sep-02-2014/SNY/report.pdf
--
GlaxoSmithKline plc Research Reports
On August 26, 2014, GlaxoSmithKline plc (GSK) announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for its once-daily use of Promacta® (eltrombopag) in patients with severe aplastic anaemia (SAA) who have had an insufficient response to immunosuppressive therapy (IST). According to GSK, SAA is a blood disorder where the bone marrow fails to make enough red blood cells, white blood cells, and platelets. The Company stated that Eltrombopag, an oral thrombopoietin receptor agonist, works by helping to induce proliferation and differentiation of bone marrow stem cells to increase production of blood cells. GSK informed that sNDA approval is based on results from an investigator-sponsored Phase II study (09-H-0154) conducted by the National Heart, Lung and Blood Institute (NHLBI) at the National Institutes of Health (NIH). GSK notified that prior to this approval, Promacta gained Breakthrough Therapy designation status from the FDA in January 2014 and Priority Review in April 2014. Dr. Paolo Paoletti, President of Oncology, GSK, said, "FDA approval of Promacta addresses a significant treatment need for this very rare but serious blood disorder in those who have failed current treatment options." The full research reports on GSK are available to download free of charge at:
http://www.analystsreview.com/Sep-02-2014/GSK/report.pdf
--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.analystsreview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review